NY-MOODY'S/METLIFE
23.4.2024 14:01:27 CEST | Business Wire | Press release
Moody’s Corporation, the world’s leading source of bold, clear and perceptive insights on exponential risk, announced today that it has been named an Official Cornerstone Partner of MetLife Stadium, home of the New York Jets and New York Giants.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423976836/en/
(Graphic: Business Wire)
As part of the multi-year partnership, Moody’s branding will be a mainstay at MetLife Stadium events, extending throughout the stadium with in-bowl signage and digital displays. Guests will first be greeted at the Moody’s Gate (pictured above) and then pass through an activation area on the plaza. Moody’s is also the naming rights partner of the Moody’s Commissioners Club, a spectacular private space in the Stadium offering guests unparalleled views and unique experiences at events.
“In trying to find organizations that align with Moody’s renewed brand of decoding complexity and finding a path forward in the face of risk or adversity, we couldn’t think of better partners than MetLife Stadium and the New York Giants and New York Jets,” said Christine Elliott, Chief Corporate Affairs Officer of Moody’s. “These institutions continually demonstrate what it takes to triumph over adversity, show us how to address complexity through teamwork and collaboration, and inspire and entertain us with each and every play. We are honored to join together with these venerable partners as the new season begins to unfold, starting this Thursday with the NFL Draft.”
“We are honored that Moody’s has chosen MetLife Stadium to showcase its new brand platform,” said Ron VanDeVeen, President and CEO of MetLife Stadium. “Having a reputable, New York-based company like Moody’s fits in perfectly with our gameday environment.”
“MetLife Stadium has been the center of entertainment since it opened in 2010,” said Hymie Elhai, President of the New York Jets. “Welcoming a new cornerstone partner like Moody’s will elevate our fan experience from the moment they enter the stadium at the Moody’s Gate and will provide an enhanced experience for our Moody’s Commissioners Club guests. We are excited to kickoff this partnership and work together on ways to reinforce our commitment to our fans.”
“Moody’s exemplifies everything we look for in a Cornerstone partner and we are thrilled to welcome them to MetLife Stadium,” said John Mara, New York Giants President and CEO. “We look forward to developing our new partnership and engaging fans across stadium events and throughout our shared hometown.”
The partnership is part of Moody’s new global branding campaign, defining Moody’s as a category of one. In a world shaped by increasingly interconnected risks, it is more difficult than ever for leaders to act with certainty. Organizations, companies, and governments need to go beyond data into context, and to go beyond context into meaning. That’s where Moody’s is in a category by itself. Through its vast data estate and unparalleled insights and analytics, Moody’s provides a compass for understanding complexity, helping customers decode risk, unlock opportunity, and inform a clear path forward in an era of exponential risk.
The financial terms of the partnership were not disclosed.
For more information, visit www.moodys.com.
About Moody’s Corporation
In a world shaped by increasingly interconnected risks, Moody’s (NYSE: MCO) data, insights, and innovative technologies help customers develop a holistic view of their world and unlock opportunities. With a rich history of experience in global markets and a diverse workforce of 15,000 across more than 40 countries, Moody’s gives customers the comprehensive perspective needed to act with confidence and thrive. Learn more at www.moodys.com.
About MetLife Stadium
MetLife Stadium, located in East Rutherford, NJ, is the home of the New York Jets and New York Giants and is one of the largest stadiums in the NFL (82,500). The stadium hosts the world’s biggest events on the world’s biggest stage and will host the FIFA World Cup 26™ Final and 7 other matches throughout the tournament. The venue annually ranks as one of the busiest stadiums in the world and has been named “Highest Grossing Stadium of the Year” 9 times by Billboard. Event highlights include Super Bowl XLVIII, NHL Stadium Series, WrestleMania, Copa America Centenario Final, 2021 Army-Navy Game, and many concerts, college football games, and international soccer matches.
About the New York Giants
A cornerstone franchise of the National Football League, the New York Football Giants began play in 1925. The Giants have won eight championships: 1927, 1934, 1938, 1956, 1986, 1990, 2007 and 2011. After twice winning two titles in five years, the Giants are the only NFL franchise with Super Bowl victories in four consecutive decades. Headquartered at the Quest Diagnostics Training Center in East Rutherford, N.J., the Giants enter their 100th season of play this fall.
About the New York Jets
The New York Jets were founded in 1959 as the New York Titans, an original member of the American Football League (AFL). The Jets won Super Bowl III, defeating the NFL’s Baltimore Colts in 1969. In 1970, the franchise joined the National Football League in the historic AFL–NFL merger that set the foundation for today’s league. As part of a commitment to its fan base through innovation and experiences, the team has created initiatives such as, its trailblazing Jets Rewards program, a state-of-the-art mobile app, and 1JD Entertainment, a comprehensive content platform that gives fans greater access to the team across all digital and social platforms. The organization takes great pride in a long-standing, year-round commitment to their community. These programs are funded by the New York Jets Foundation and look to positively influence the lives of young men and women in the tri-state area, particularly in disadvantaged communities. The organization supports the efforts of the Lupus Research Alliance, youth football and numerous established charitable organizations and causes sponsored by the NFL. The New York Jets play in MetLife Stadium, which opened in 2010, and are headquartered at the Atlantic Health Jets Training Center in Florham Park, New Jersey. For more information about the New York Jets visit newyorkjets.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423976836/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 14:00:00 CEST | Press release
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duratio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
